Juan G Abraldes

University of Barcelona, Barcino, Catalonia, Spain

Are you Juan G Abraldes?

Claim your profile

Publications (197)1585.02 Total impact

  • Lourdes Cabrera · Juan G. Abraldes
    [Show abstract] [Hide abstract]
    ABSTRACT: Cirrhosis and portal hypertension are associated with intrahepatic endothelial dysfunction, which creates a proinflammatory and profibrotic environment and increases hepatic resistance and portal pressure. Statins have shown to improve the liver endothelial dysfunction and decrease the portal pressure in preclinical models of cirrhosis. In humans, they have shown anti-inflmatory and antifibrotic effects in the liver. This suggests that statins can target several pathogenic events in cirrhosis and have potential to improve the prognosis in these patients. This needs further evaluation in adequately designed randomized trials with clinical endpoints.
    No preview · Article · Jan 2016
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background & aims: The combination of β-blockers and band ligation is the standard approach to prevent variceal rebleeding, but bleeding recurs and mortality is high. The lipid-lowering drug simvastatin decreases portal pressure, improves hepatocellular function, and might reduce liver fibrosis. We assessed whether adding simvastatin to standard therapy could reduce rebleeding and death after variceal bleeding in patients with cirrhosis. Methods: We performed a multicenter, double-blind, parallel trial of 158 patients with cirrhosis receiving standard prophylaxis to prevent rebleeding (a β-blocker and band ligation) in Spain from October 2010 through October 2013. Within 10 days of bleeding, subjects were randomly assigned, but stratified by Child-Pugh scores of A or B vs C, to groups given simvastatin (20 mg/day the first 15 days, 40 mg/day thereafter; n=69) or placebo (n=78). Patients were followed for as long as 24 months. The primary endpoint was a composite of rebleeding and death, and main secondary endpoints were the individual components of the composite (death and rebleeding) RESULTS: The primary endpoint was met by 30/78 patients in the placebo group and 22/69 in the simvastatin group (P=.423). Seventeen patients in the placebo group died (22%) vs 6 patients in the simvastatin group (9%) (hazard ratio for adding simvastatin to therapy, 0.39; 95% confidence interval, 0.15-0.99; P=.030). Simvastatin did not increase survival of patients with Child-Pugh class C cirrhosis. Rebleeding occurred in 28% of patients in the placebo group and 25% in the simvastatin group (P=.583). Serious adverse events occurred in 53% of patients in the placebo group and 49% in the simvastatin group (P=.752); the percentages of serious adverse events related to therapy were 11% in the placebo group vs 8% in the in the simvastatin group (P=.599). Two patients in the simvastatin group, each with advanced liver disease, developed rhabdomyolysis. Conclusion: In a randomized controlled trial, addition of simvastatin to standard therapy did not reduce rebleeding but was associated with a survival benefit for patients with Child-Pugh class A or B cirrhosis. Survival was not the primary endpoint of the study, so these results require validation. The incidence of rhabdomyolisis in patients receiving 40 mg/day simvastatin was higher than expected. European Clinical Trial Database no: EUDRACT 2009-016500-24.
    No preview · Article · Jan 2016 · Gastroenterology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-selective β-blockers are useful to prevent bleeding in patients with cirrhosis and large varices but not to prevent the development of varices in those with compensated cirrhosis and portal hypertension (PHT). This suggests that the evolutionary stage of PHT may influence on response to β-blockers. To characterize the hemodynamic profile of each stage of PHT in compensated cirrhosis and the response to β-blockers according to such stage, we performed a prospective, multicenter (tertiary care setting), cross sectional study. Hepatic venous pressure gradient (HVPG) and systemic hemodynamic were measured in 273 patients with compensated cirrhosis, before and after i.v. propranolol (0.15 mg/Kg). 194 patients had an HVPG ≥10 mmHg (clinically significant PHT: CSPH), either with no-varices (n= 80) or small varices (n= 114), and 79 had an HVPG >5 and <10 mmHg (subclinical-PHT). Patients with CSPH had higher liver stiffness (P< 0.001), worse MELD score (P<0.001), more porto-systemic collaterals (P= 0.01) and splenomegaly (P= 0.01) on ultrasound and lower platelet count (P<0.001) than those with subclinical-PHT. Patients with CSPH had lower systemic vascular resistance (1336±423 vs 1469±335 dyne.s.cm−5, P<0.05) and higher cardiac index (3.3±0.9 vs 2.8±0.4 L/min/m2, P<0.01). After propranolol, the HVPG decreased significantly in both groups, although the reduction was greater in those with CSPH (-16±12% vs -8±9%, P<0.01). The HVPG decreased ≥10% from baseline in 69% of patients with CSPH vs 36% with sub-clinical-PHT (P<0.001) and decreased ≥20% in 40% vs 12%, respectively (P=0.001). Conclusion: Patients with subclinical-PHT have less hyperdynamic circulation and significantly lower portal pressure reduction after acute β-blockade than those with CSPH. This suggests that β-blockers are more suitable to prevent decompensation of cirrhosis in patients with CSPH than in earlier stages. This article is protected by copyright. All rights reserved.
    No preview · Article · Sep 2015 · Hepatology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-selective beta-blockers (NSBB) are widely used since they have been proved effective in the prophylaxis of acute variceal bleeding (AVB). However, still a significant proportion of patients experience AVB whilst on treatment with NSBB and their impact on prognosis of AVB is unknown. The present study aimed at assessing the effect of being on prophylactic therapy with NSBB on 5-day failure and 6-week mortality of cirrhotic patients admitted with AVB. 142 patients were included: 49 patients were receiving prophylactic therapy with NSBB (NSBB group) and 93 patients were not (control group). There were some differences in the baseline characteristics between the groups: higher proportion of alcoholic etiology and active alcoholism (37% vs. 10%), higher platelets count and lower hematocrit at admission in the control group. However, the severity of AVB and initial treatment were similar. 5-day failure occurred in 20% of patients (14% in NSBB vs. 24% in controls; p = 0.27). The adjusted OR for 5-day failure under NSBB was 2.46; 95% CI: 0.53-11.37; p=0.25. Nineteen patients (13%) died and 2 had liver transplantation within 6-weeks. The probability of survival at 6 weeks was 96% in the NSBB group and 82% in the control group (p=0.02). After adjusting by propensity score and model for end-stage liver disease (MELD) score, the NSBB adjusted OR for 6-week mortality was 0.38; 95% CI: 0.05- 2.63; p=0.32. The estimated association between NSBB with both 5-day failure and 6-week mortality was homogenous across all MELD spectrums. Our study indicates that being under prophylactic NSBB treatment is not a negative prognostic indicator for the short-term survival of cirrhotic patients admitted with AVB. This article is protected by copyright. All rights reserved. © 2015 by the American Association for the Study of Liver Diseases.
    No preview · Article · Sep 2015 · Hepatology
  • Juan G Abraldes · Puneeta Tandon
    [Show abstract] [Hide abstract]
    ABSTRACT: Variceal bleeding is the most serious complication of portal hypertension. All cirrhotic patients should be screened endoscopically for varices which are present in about 30% of compensated and 60% of decompensated patients at diagnosis. In patients without varices, endoscopy surveillance should be continued every 2 years. Patients with high-risk varices (moderate or large in size, or with red color signs, or in Child-Pugh C patients) should be treated with a nonselective β-blocker to prevent bleeding (propranolol, nadolol or carvedilol). Endoscopic banding ligation is also effective for the prevention of first bleeding, and it is the first choice in patients with contraindications or intolerance to β-blockers. Acute variceal hemorrhage still has a high mortality rate (around 15%) and requires intensive care management and conservative blood transfusion policy. Treatment is based on the combined use of vasoactive drugs, endoscopic band ligation and prophylactic antibiotics. Failures are best managed by transjugular intrahepatic portosystemic shunt (TIPS). Balloon tamponade or specifically designed covered esophageal stents can be used as a bridge to definitive therapy in unstable patients. Early, preemptive TIPS might be the first choice in patients at high risk of failure (Child-Pugh B with active bleeding or Child-Pugh C up to 13 points). Patients surviving a variceal bleeding are at high risk of rebleeding. A combination of β-blockers and endoscopic band ligation is the most effective therapeutic approach. Preliminary data suggest that the addition of simvastatin increases survival in these patients. © 2015 S. Karger AG, Basel.
    No preview · Article · Jul 2015 · Digestive Diseases
  • Source
    C J Karvellas · J G Abraldes · Y Arabi · A Kumar

    Full-text · Article · Jul 2015 · Alimentary Pharmacology & Therapeutics
  • Source

    Preview · Article · Jun 2015 · Journal of Hepatology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Improving estimation of long-term survival of patients with end-stage liver disease after orthotopic liver transplantation (OLT) would optimize decisions on eligibility for transplant. We aimed to externally validate previously derived Charlson Comorbity Index for OLT (CCI-OLT); subsequently, we developed a new model to predict 5-year mortality after transplant. Material and methods: This single center retrospective cohort study included 524 consecutive adult cirrhotic patients who underwent OLT in 2002-2012. External validation of CCI-OLT used Kaplan-Meier method. Derivation of the new predictive model used Cox proportional hazards regression. Results: One-, 3-, and 5-year cumulative survival after OLT was 89%, 80%, and 73%, respectively. CCI-OLT was not associated with 5-year mortality after transplant (P = 0.34). We derived and internally validated a new predictive model of 5-year mortality after OLT based on six pre-transplant characteristics of patients: age, body mass index, hepatitis C, hepatic encephalopathy, intensive care unit stay at transplant, and live donor (C-index = 0.64). We further developed a nomogram to estimate individual probability of 1-, 3-, and 5-year survival after OLT. Conclusions: In our cohort, CCI-OLT was not associated with survival following transplant. The new predictive model discriminative capacity was only modest, suggesting that pre-transplant characteristics are of limited value in predicting post-transplant outcomes in thoroughly selected patients.
    No preview · Article · May 2015 · Annals of hepatology: official journal of the Mexican Association of Hepatology
  • [Show abstract] [Hide abstract]
    ABSTRACT: The late and fast developments in the field of viral hepatitis were highly expected in the 2014 AASLD Liver Meeting (R). Several combinations using direct acting antivirals (DAAs) showed high rates of sustained virological response (similar to 95%). Importantly, high cure rates were also demonstrated in patients with previous treatment failures, decompensated cirrhosis and hepatitis C recurrence after transplantation, making it clear that the interferon era is over (not so clear for ribavirin, which might still have a role in difficult-to-treat populations). Importantly, sustained virological response was associated with an improvement in liver function (MELD and Child-Pugh scores) in patients with advanced liver disease. In the field of liver cirrhosis, there were relevant data assessing the optimal empirical antibiotic therapy in patients with spontaneous bacterial peritonitis and high risk of resistant bacteria, as well as studies evaluating the role of terlipressin in type I hepatorenal syndrome and in septic shock. Regarding hepatic encephalopathy, two randomized trials suggest that the manipulation of the microbioma in patients with cirrhosis may have a role in the management of this complication. Some novel data on NASH support the beneficial effect of bariatric surgery (after failure of lifestyle intervention) in morbid obese patients with such diagnosis: clinical and histological improvements after surgery were evident in most patients with sufficient follow-up. A few controlled studies focused on the treatment of severe acute alcoholic hepatitis. Finally, several studies on hepatocellular carcinoma (HCC) were presented, covering topics such as ultrasound screening in cirrhosis, cryoablation treatment of early HCC and the relevance of downstaging in patients with HCC awaiting liver transplantation.
    No preview · Article · May 2015 · Journal of Hepatology
  • Constantine J. Karvellas · Juan G. Abraldes · Anand Kumar

    No preview · Article · Apr 2015 · Gastroenterology

  • No preview · Article · Apr 2015 · Journal of Hepatology

  • No preview · Article · Apr 2015 · Journal of Hepatology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alcoholic hepatitis (AH) frequently progresses to multiple organ failure (MOF) and death. However, the driving factors are largely unknown. At admission, patients with AH often show criteria of systemic inflammatory response syndrome (SIRS) even in the absence of an infection. We hypothesize that the presence of SIRS may predispose to MOF and death. To test this hypothesis, we studied a cohort including 162 patients with biopsy-proven AH. The presence of SIRS and infections was assessed in all patients, and multivariate analyses identified variables independently associated with MOF and 90-day mortality. At admission, 32 (19.8%) patients were diagnosed with a bacterial infection, while 75 (46.3%) fulfilled SIRS criteria; 58 patients (35.8%) developed MOF during hospitalization. Short-term mortality was significantly higher among patients who developed MOF (62.1% versus 3.8%, P<0.001). The presence of SIRS was a major predictor of MOF (odds ratio=2.69, P=0.025) and strongly correlated with mortality. Importantly, the course of patients with SIRS with and without infection was similar in terms of MOF development and short-term mortality. Finally, we sought to identify serum markers that differentiate SIRS with and without infection. We studied serum levels of high-sensitivity C-reactive protein, procalcitonin, and lipopolysaccharide at admission. All of them predicted mortality. Procalcitonin, but not high-sensitivity C-reactive protein, serum levels identified those patients with SIRS and infection. Lipopolysaccharide serum levels predicted MOF and the response to prednisolone. Conclusion: In the presence or absence of infections, SIRS is a major determinant of MOF and mortality in AH, and the mechanisms involved in the development of SIRS should be investigated; procalcitonin serum levels can help to identify patients with infection, and lipopolysaccharide levels may help to predict mortality and the response to steroids. (Hepatology 2015;62:762-772)
    Full-text · Article · Mar 2015 · Hepatology
  • Juan G. Abraldes · Puneeta Tandon
    [Show abstract] [Hide abstract]
    ABSTRACT: Non-selective beta-blockers (NSBBs) have been used for over 30 years in the treatment of portal hypertension in patients with cirrhosis. They have proven efficacy in preventing first variceal bleeding and rebleeding and in reducing mortality. NSBBs might additionally reduce the risk of infections in cirrhosis. Recent data suggest that patients with refractory ascites or that have experienced a spontaneous bacterial peritonitis might have an increased mortality if they are treated with NSBBs. The lack of randomized trials, and the conflicting results from observational studies, makes it difficult to reach a definitive conclusion. In this article, we review the current evidence on the benefits and harms of NSBBs in cirrhosis and provide recommendations for their use in special populations.
    No preview · Article · Mar 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: For patients awaiting liver transplantation, we aimed to determine the prevalence and predictors of insufficient protein intake as well as to determine whether very low protein intake was an independent predictor of malnutrition and mortality. Materials and Methods: Adults with cirrhosis who were activated on our local liver transplant waiting list between January 2000 and October 2009 were included. Estimated protein intake was derived from dietary records. Patients with incomplete dietary records were excluded. Multivariable logistic regression and competing risk analysis were used. Results: Of 742 potential patients, 112 were excluded due to insufficient data, leaving 630 patients for evaluation. Mean protein intake was 1.0 ± 0.36 g/kg/d and only 24% of patients met the expert consensus recommended threshold of > 1.2 g/kg of protein per day. Very low protein intake (< 0.8 g/kg/d) was associated with worse liver disease severity (as measured by Child-Pugh or MELD). Protein intake below 0.8 g/kg/d was an independent predictor both of malnutrition as measured by the subjective global assessment (adjusted odds ratio [95% confidence interval (CI)]: 2.0 [1.3-3.0]) and of transplant waiting list mortality (adjusted hazard ratio [95% CI]: 1.8 [1.2-2.7]). Conclusion: In this large cohort of liver transplant waitlisted patients, very low protein intake was prevalent and independently associated with malnutrition and mortality. Unlike many other prognostic factors, protein intake is potentially modifiable. Prospective studies are warranted to evaluate the effect of targeted protein repletion on clinically relevant outcomes such as muscle mass, muscle function, immune function, and mortality. © 2015 American Society for Parenteral and Enteral Nutrition.
    No preview · Article · Feb 2015 · Nutrition in Clinical Practice
  • Source
    C. J. Karvellas · J. G. Abraldes · Y. M. Arabi · A. Kumar
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Spontaneous bacterial peritonitis (SBP)-associated septic shock carries significant mortality in cirrhosis.AimTo determine whether practice-related aspects of antimicrobial therapy contribute to high mortality.Methods Retrospective cohort study of all (n = 126) cirrhotics with spontaneous bacterial peritonitis (neutrophil count >250 or positive ascitic culture)-associated septic shock (1996–2011) from an international, multicenter database. Appropriate antimicrobial therapy implied either in vitro activity against a subsequently isolated pathogen (culture positive) or empiric management consistent with broadly accepted norms (culture negative).ResultsOverall hospital mortality was 81.8%. Comparing survivors (n = 23) with non-survivors (n = 103), survivors had lower Acute Physiology and Chronic Health Evaluation (APACHEII) (mean ± s.d.; 22 ± 7 vs. 32 ± 8) and model for end-stage liver disease (MELD) (24 ± 9 vs. 34 ± 11) scores and serum lactate on admission (4.9 ± 3.1 vs. 8.9 ± 5.3), P < 0.001 for all. Survivors were less likely to receive inappropriate initial antimicrobial therapy (0% vs. 25%, P = 0.013) and received appropriate antimicrobial therapy earlier [median 1.8 (1.1–5.2) vs. 9.5 (3.9–14.3) h, P < 0.001]. After adjusting for covariates, APACHEII [OR, odds ratio 1.45 (1.04–2.02) per 1 unit increment, P = 0.03], lactate [OR 2.34 (1.04–5.29) per unit increment, P = 0.04] and time delay to appropriate antimicrobials [OR 1.86 (1.10–3.14) per hour increment, P = 0.02] were significantly associated with increased mortality.Conclusions Cirrhotic patients with septic shock secondary to spontaneous bacterial peritonitis have high mortality (>80%). Each hour of delay in appropriate antimicrobial therapy was associated with a 1.86 times increased hospital mortality. Admission APACHEII and serum lactate also significantly impacted hospital mortality. Earlier initiation of appropriate antimicrobial therapy could substantially improve outcome.
    Full-text · Article · Feb 2015 · Alimentary Pharmacology & Therapeutics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The late and fast developments in the field of viral hepatitis were highly expected in the 2014 AASLD Liver Meeting. Several combinations using direct acting antivirals (DAAs) showed high rates of sustained virological response (∼ 95%). Importantly, high cure rates were also demonstrated in patients with previous treatment failures, decompensated cirrhosis and hepatitis C recurrence after transplantation, making it clear that the interferon era is over (not so clear for ribavirin, which might still have a role in difficult-to-treat populations). Importantly, sustained virological response was associated with an improvement in liver function (MELD and Child-Pugh scores) in patients with advanced liver disease. In the field of liver cirrhosis, there were relevant data assessing the optimal empirical antibiotic therapy in patients with spontaneous bacterial peritonitis (SBP) and high risk of resistant bacteria, as well as studies evaluating the role of terlipresin in type I hepatorenal syndrome and in septic shock. Regarding hepatic encephalopathy, two randomized trials suggest that the manipulation of the microbioma in patients with cirrhosis may have a role in the management of this complication. Some novel data on NASH support the beneficial effect of bariatric surgery (after failure of life-style intervention) in morbid obese patients with such diagnosis: clinical and histological improvements after surgery were evident in most patients with sufficient follow-up. A few controlled studies focused on the treatment of severe acute alcoholic hepatitis. Finally, several studies on hepatocellular carcinoma (HCC) were presented in the Liver Meeting, covering topics such as ultrasound screening in cirrhosis, cryoablation treatment of early HCC and the relevance of downstaging in patients with HCC awaiting liver transplantation. Copyright © 2015. Published by Elsevier B.V.
    Preview · Article · Jan 2015
  • Juan G. Abraldes · Philippe Sarlieve · Puneeta Tandon
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatic venous pressure gradient (HVPG) measurement is one of the most useful techniques in the field of hepatology. The HVPG is close to the best surrogate marker in chronic liver diseases. It reflects disease severity and has strong prognostic value with regard to survival and decompensation in patients with compensated cirrhosis, during acute bleeding and before liver resection surgery. Furthermore, repeat measurements of the HVPG provide unique information on the response to the medical treatment of portal hypertension and represent an invaluable tool for developing new drugs for this syndrome. Transjugular liver biopsy adds very little time or complications to an HVPG procedure, and allows adequate liver sampling in several circumstances in which the percutaneous approach is contraindicated. The use of automated cutting needles, as compared to aspiration needles, is associated with better quality samples.
    No preview · Article · Jan 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Real-time shear wave elastography (RT-SWE) might be useful to assess the severity of portal hypertension; reliability criteria for measurement are needed. We prospectively included 88 consecutive patients undergoing hepatic venous pressure gradient measurement (HVPG, reference standard) for portal hypertension. Liver stiffness (LS) was measured by RT-SWE and by transient elastography (TE). Spleen stiffness (SS) was measured by RT-SWE. Reliability criteria for RT-SWE were searched, and the accuracy of these techniques to identify HVPG⩾10 mmHg (clinically significant portal hypertension, CSPH) was tested and internally validated by bootstrapping analysis. LS and SS by RT-SWE were feasible respectively in 87 (99%) and 58 (66%) patients. Both correlated with HVPG (LS: R=0.611, p<0.0001 and SS: R=0.514,p<0.0001). LS performed well for diagnosing CSPH (optimism corrected AUROC 0.858). Reliability of measurements was influenced by standard deviation (SD)/median ratio and depth. SD/median ⩽0.10 and depth of measurement <5.6 cm were associated to 96.3% well classified for CSPH, while when one or none of the criteria were fulfilled the rated was, respectively, 76.4% and 44.4%. Measurements fulfilling at least one criterion were considered acceptable; in these patients RT-SWE performance to detect CSPH was excellent (AUROC 0.939; 95%CI: 0.865-1.000;p<0.0001; best cut-off: 15.4 kPa). LS by RT-SWE and by TE were strongly correlated (R=0.795,p<0.0001) and performed similarly both in "per protocol" and in "intention-to-diagnose" analysis after applying reliability criteria. Data CONCLUSIONS: LS by RT-SWE is an accurate method to diagnose CSPH if reliability criteria (SD/median ⩽0.10 and/or depth <5.6 cm) are fulfilled. Copyright © 2014. Published by Elsevier B.V.
    No preview · Article · Dec 2014 · Journal of Hepatology
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the liver, the transcription factor, Kruppel-like factor 2 (KLF2), is induced early during progression of cirrhosis to lessen the development of vascular dysfunction; nevertheless, its endogenous expression results insufficient to attenuate establishment of portal hypertension and aggravation of cirrhosis. Herein, we aimed to explore the effects and the underlying mechanisms of hepatic KLF2 overexpression in in vitro and in vivo models of liver cirrhosis. Activation phenotype was evaluated in human and rat cirrhotic hepatic stellate cells (HSC) treated with the pharmacological inductor of KLF2 simvastatin, with adenovirus codifying for this transcription factor (Ad-KLF2), or vehicle, in presence/absence of inhibitors of KLF2. Possible paracrine interactions between parenchymal and non-parenchymal cells overexpressing KLF2 were studied. Effects of in vivo hepatic KLF2 overexpression on liver fibrosis and systemic and hepatic haemodynamics were assessed in cirrhotic rats. KLF2 upregulation profoundly ameliorated HSC phenotype (reduced α-smooth muscle actin, procollagen I and oxidative stress) partly via the activation of the nuclear factor (NF)-E2-related factor 2 (Nrf2). Coculture experiments showed that improvement in HSC phenotype paracrinally ameliorated liver sinusoidal endothelial cells probably through a vascular endothelial growth factor-mediated mechanism. No paracrine interactions between hepatocytes and HSC were observed. Cirrhotic rats treated with simvastatin or Ad-KLF2 showed hepatic upregulation in the KLF2-Nrf2 pathway, deactivation of HSC and prominent reduction in liver fibrosis. Hepatic KLF2 overexpression was associated with lower portal pressure (-15%) due to both attenuations in the increased portal blood flow and hepatic vascular resistance, together with a significant improvement in hepatic endothelial dysfunction. Exogenous hepatic KLF2 upregulation improves liver fibrosis, endothelial dysfunction and portal hypertension in cirrhosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
    No preview · Article · Dec 2014 · Gut

Publication Stats

5k Citations
1,585.02 Total Impact Points

Institutions

  • 2002-2016
    • University of Barcelona
      • Department of Medicine
      Barcino, Catalonia, Spain
  • 2014-2015
    • University of Alberta
      • Division of Gastroenterology
      Edmonton, Alberta, Canada
  • 2000-2015
    • Hospital Clínic de Barcelona
      • Servicio de Hepatología
      Barcino, Catalonia, Spain
  • 2010-2014
    • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
      Barcino, Catalonia, Spain
  • 2002-2014
    • IDIBAPS August Pi i Sunyer Biomedical Research Institute
      Barcino, Catalonia, Spain
  • 2011
    • Instituto de Salud Carlos III
      Madrid, Madrid, Spain
  • 2008-2011
    • Institut Marqués, Spain, Barcelona
      Barcino, Catalonia, Spain
  • 2009
    • Centro de Investigación Biomédica Esther Koplowitz
      Barcino, Catalonia, Spain
    • Hospital Universitario Ramón y Cajal
      • Departamento de Medicina Interna
      Madrid, Madrid, Spain
  • 2007
    • Hospital Medica Sur
      Ciudad de México, Mexico City, Mexico
    • Hospital General Universitario de Alicante
      Alicante, Valencia, Spain
  • 2006
    • Hospital General Universitario Gregorio Marañón
      Madrid, Madrid, Spain
  • 2004-2006
    • Yale University
      • • Section of Digestive Diseases
      • • Department of Internal Medicine
      New Haven, Connecticut, United States
  • 2005
    • Azienda Ospedaliero Universitaria Careggi
      • Department of Hematology
      Firenzuola, Tuscany, Italy